A Prospective, Multicenter, Single Group Assignment Study for Evaluating the Safety and Effectiveness of MitralStitch Mitral Valve Repair System in Patients With Moderate to Severe and Severe Mitral Regurgitation.
试验速览
- 阶段
- 不适用
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- The success rate
研究概览
简要总结
The main objective is to assess the effectiveness and safety of the MitralStitch repair system in patients with moderate to severe and severe mitral regurgitation.
详细描述
The clinical trial was designed as a prospective, multicenter, single group assignment study. The participants with moderate to severe and severe mitral valve regurgitation will receive a transapical beating-heart mitral valve repair surgery using MitralStitch mitral valve repair system after signed the informed consent. The follow-up will be conducted after 30 days, 3 months, 6 months and 12 months of the operation.
The following conditions evaluate the performance of the system and the safety and efficiency of using MitralStitch mitral valve repair system in treating patients with severe mitral regurgitation.
The none occurrence of these conditions will be approved as the main validity index: death, mitral valve related surgery without mitral valve failure and moderate or severe mitral regurgitation (MR > 2+). The secondary validity index was technical success rate, instrument success rate, surgical success rate, cardiac function improvement and quality of life improvement. And the safety evaluation indicators were assessed by the incidence of major adverse events, adverse events, serious adverse events, and device defects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
No masking
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 yrs
- •Moderate to severe (3+) or severe (4+) mitral valve regurgitation confirmed by echocardiography (defined as MR >2+);
- •NYHA functional class II-V (Appendix 3);
- •Anatomically suitable for mitral valve repair;
- •40mm ≤LVESD≤55 mm; 25% ≤LVEF ≤60%; tolerable for small incision thoracic surgery;
- •Mitral valve diameter ≤45mm;
- •The independent expert committee of this study determined that surgical operation was contraindicated or high-risk, and the recommended reference standard was: surgical valve replacement with STS score ≥ 8； or surgical valve repair with STS score ≥ 6； or other risk factors (e.g., There are at least two moderate to severe indicators of weakness; potential operational disorders; at least major organ dysfunction that cannot be improved after surgery, etc.)
- •The subject or the subject's legal representative fully understand and agree to join to the clinic trial.
排除标准
- •Echocardiographic evidence of intracardiac mass, thrombus or vegetation;
- •Severe mitral valve calcification;
- •Concomitant with greater than moderate aortic stenosis or regurgitation;
- •Mitral regurgitation caused by special pathological mechanisms, such as leaflet perforation and leaflet fissure;
- •Severe untreated coronary artery stenosis requiring revascularization; or with other cardiovascular disease requiring surgical treatment;
- •Hypertrophic cardiomyopathy with or without obstruction, restrictive cardiomyopathy, constrictive pericarditis, or other structural heart diseases that cause heart failure in patients expect dilated cardiomyopathy;
- •Myocardial infarction was performed within 4 weeks before the intervention;
- •Any vascular intervention, cardiac surgery, cardiac resynchronization therapy (CRT, CRT-D), and an implantation of implantable cardioverter defibrillator (ICD) were performed within 30 days before the intervention;
- •Any heart transplantation, mitral valve surgery or percutaneous mitral valve operation were performed before the intervention;
- •Life expectancy is less than 12 months;
- •History of, or active, rheumatic heart disease;
- •Active phase of bacterial endocarditis;
- •The active infections require concurrent antibiotic treatment;
- •History of acute peptic ulcer or upper gastrointestinal bleeding within 3 months;
- •Dysplasia of the blood system, including granulocytopenia (WBC < 3×109/L), acute anemia (HB < 90g/L), thrombocytopenia (PLT < 50×109/L), hemorrhagic constitution, and coagulopathy；
- •Modified Rankin scale ≥4；
- •Pregnant or lactating women;
- •The subject is suffered from a disease which may cause difficulty in evaluating the treatment (e.g., cancer, infection, severe metabolic disease, psychosis, etc.); or special cases were evaluated by the local experimental center heart team as not suitable for the surgical application of this clinical trial instrument;
- •Participants who have participated in clinical trials of any drug and/or medical device within 1 month before this study;
- •In the judgment of the Investigator, patients were not compliant enough to complete the study as required.
研究组 & 干预措施
MitralStitch repair system
Experimental group is allocated to use novel mitral vavle repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
干预措施: MitralStitch (Device)
结局指标
主要结局
The success rate
时间窗: 1 year
Combined incidence of freedom from: death, surgery for Valve Dysfunction, and MR \> 2+ (moderate to severe (3+) or severe (4+) mitral regurgitation) at 12 months
次要结局
- The instant procedural success(Immediately after repair)
- The success of the repair system(12 months)
- Living quality(12 months)
- The success of the surgery(1 month)
- New York Heart Association (NYHA) class(12 months)
- Incidence of major adverse events(MAE)(12 months)